18 and older, female only, with Recurrent Epithelial Cancer of Ovary or Primary Peritoneal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
To Assess Overall Clinical Response Rates Per RECIST Criteria.Primary· 1 year,4 months
Analysis of (with safety lead-in) trial of combined Avelumab (MSB0010718C) anti-PD-L1checkpoint blockade with SAbR for Recurrent Ovarian and peritoneal ,fallopian tube cancer (ROPT) is to assess overall clinical response rates per RECIST criteria .
Group
Value
95% CI
Recurrent Ovarian and Peritoneal ,Fallopian Tube Cancer (ROP
0
Overall SurvivalSecondary· 1 year, 4 months
Patients were started on alternative therapy and were not followed after starting alternative therapy.
Study was stopped because drug was found to be ineffective by the pharmaceutical company
Group
Value
95% CI
Single Arm
NA
Adverse events — posted to ClinicalTrials.gov
Time frame: The adverse event were 6 months from enrollment.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Programmed death-1 receptor ligand (PD-L1) the ligand for PD-1 is a key therapeutic target in the reactivation of the immune response against multiple cancers. Pharmacologic inhibitors of PD-1 have also demonstrated significant anti-tumor activity and are currently under active clinical exploration. avelumab (MSB0010718C; anti-PD-L1 is a fully human anti-PD-L1 igG1 antibody that has shown promising efficacy and an acceptable safety profile in multiple tumor types.
Radiation therapy (RT) is one of the mainstream treatments of cancer therapy along with surgery and chemotherapy, yet RT is the only treatment that does not leave the patients immunocompromised (unlike chemotherapy) and keeps the dying tumor / antigen depot within the host (unlike surgery), providing an opportunity for antigen presentation. Therefore, RT is a rational choice to combine with immunotherapy for cancer treatment.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
· Phase 1, PHASE2
· terminated
NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
· Phase 1, PHASE2
· withdrawn
NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
· Phase 2
· recruiting
NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L
· Phase 2
· withdrawn
NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours
· Phase 1
· recruiting
Other recruiting trials for Recurrent Epithelial Cancer of Ovary
Currently open trials in the same condition.
NCT05335993 — A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent O
· Phase 2
· active not recruiting
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain
· recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB)
· NA
· not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans
· Phase 2
· not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
· NA
· not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 12 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03312114.